Hoerauf Achim
Institute of Medical Parasitology, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany.
Curr Opin Infect Dis. 2003 Oct;16(5):403-10. doi: 10.1097/00001432-200310000-00006.
Infections with the filarial nematodes affect more than 150 million people mainly in the tropics. The very successful efforts to control filarial infections, however, have to be sustained by new tools that require long-term commitment to research. This review, focusing on reports from 2002 and 2003, highlights recent advances in research on immunology, understanding of pathogenesis and drug development in lymphatic filariasis and onchocerciasis research with potential relevance to the generation of new tools for control.
Dramatic improvement has been achieved in the control of lymphatic filariasis and onchocerciasis by vector control and mass treatment with microfilaricidal drugs. Additional tools that could help in regional elimination or, ultimately, eradication of filariasis may arise from the development of new drugs or a vaccine. Research into the immune responses mediating protection or pathology has provided new insights into the pathways that lead to effector function and immunosuppression, such as T regulatory responses, as well as into genetic predispositions from the host's side, and to the identification of vaccine candidates that show protection in animal models. Recognition of the role the Wolbachia endosymbionts may play in activating the innate immune system has altered our understanding of immunopathology of filariasis and adverse reactions to microfilaricidal drugs. Wolbachia spp. have also proven to be suitable targets for the development of a long-term sterilizing or potentially macrofilaricidal drug.
This review summarizes recent developments in the control of filariasis, in particular lymphatic filariasis and onchocerciasis, as well as in modern research into the immunity of filariasis and new drug development that could lead to additional tools necessary for sustained success in filariasis control.
丝虫线虫感染主要影响热带地区超过1.5亿人。然而,控制丝虫感染的卓有成效的努力必须依靠需要长期致力于研究的新工具来维持。本综述聚焦于2002年和2003年的报告,重点介绍了淋巴丝虫病和盘尾丝虫病研究在免疫学、发病机制理解以及药物开发方面的最新进展,这些进展可能与开发新的控制工具相关。
通过病媒控制和使用杀微丝蚴药物进行群体治疗,淋巴丝虫病和盘尾丝虫病的控制取得了显著进展。新药或疫苗的开发可能会产生有助于区域消除或最终根除丝虫病的其他工具。对介导保护或病理的免疫反应的研究为导致效应功能和免疫抑制的途径提供了新的见解,如调节性T细胞反应,以及宿主方面的遗传易感性,并有助于识别在动物模型中显示出保护作用的候选疫苗。认识到沃尔巴克氏体共生菌在激活先天免疫系统中可能发挥的作用,改变了我们对丝虫病免疫病理学和对杀微丝蚴药物不良反应的理解。沃尔巴克氏体也已被证明是开发长期绝育或潜在杀成虫药物的合适靶点。
本综述总结了丝虫病控制方面的最新进展,特别是淋巴丝虫病和盘尾丝虫病,以及丝虫病免疫和新药开发的现代研究,这些研究可能会带来丝虫病控制持续成功所需的其他工具。